Palifermin Tested to Block Autoimmunity After Alemtuzumab in MS Patients
A Phase 1/2 trial explored whether thymic T cell regeneration via palifermin could prevent dangerous secondary autoimmunity after alemtuzumab MS therapy.
Summary
Alemtuzumab is a powerful therapy for multiple sclerosis that depletes immune cells, but it carries a serious side effect: secondary autoimmune diseases that can emerge months or years later as the immune system rebuilds itself. This trial tested whether palifermin (Kepivance), a drug that stimulates the thymus to regenerate healthy T cells, could prevent this problem. The study was sponsored by Cambridge University Hospitals and registered as a Phase 1/2 trial. Unfortunately, the trial was terminated before completion, meaning definitive results were not established. The underlying concept — that promoting thymic regeneration produces a more balanced, self-tolerant immune system — remains scientifically compelling and relevant to aging biology, since thymic involution is a central driver of immune aging and age-related disease vulnerability.
Detailed Summary
Multiple sclerosis (MS) is a debilitating autoimmune disease of the central nervous system. Alemtuzumab, a monoclonal antibody that depletes lymphocytes, has shown remarkable efficacy in halting MS progression — but it creates a paradox: by clearing the immune system, it triggers a dangerous rebound during repopulation, with up to 30–40% of treated patients developing new secondary autoimmune conditions, most commonly thyroid disease but also immune thrombocytopenia and nephropathy.
This Phase 1/2 clinical trial, sponsored by Cambridge University Hospitals NHS Foundation Trust, hypothesized that palifermin (Kepivance), a keratinocyte growth factor, could address this problem. Palifermin stimulates thymic epithelial cells, promoting thymic output of naive, self-tolerant T cells. The logic is that a more regulated, thymus-driven immune reconstitution would produce fewer autoreactive clones and therefore less secondary autoimmunity.
The thymic angle gives this trial direct relevance to longevity science. The thymus begins involuting in early adulthood, progressively reducing naive T cell output — a process central to immunosenescence and increased susceptibility to infection, cancer, and autoimmunity in older adults. Strategies that reactivate or support thymic function are therefore of broad interest to the aging-biology community, beyond the specific MS context.
The trial was ultimately terminated before completion. No efficacy or safety results are available in the public record from this abstract. The reasons for termination are not disclosed in the available information, which is a significant limitation.
Despite the early termination, the scientific hypothesis remains live. Thymic regeneration as a strategy to improve immune reconstitution quality — whether after lymphodepletion therapies or as a general anti-aging intervention — continues to attract research attention. Palifermin and related growth factors may yet find a role in immune rejuvenation protocols.
Key Findings
- Trial tested palifermin to prevent secondary autoimmunity after alemtuzumab lymphodepletion in MS patients.
- Palifermin targets thymic epithelial cells to boost output of self-tolerant naive T cells.
- Thymic regeneration strategy is directly relevant to immunosenescence and immune aging biology.
- Trial was terminated early; no efficacy or safety results are publicly available from this study.
- Secondary autoimmunity affects up to 30–40% of alemtuzumab-treated MS patients, representing a major unmet need.
Methodology
This was a Phase 1/2 interventional clinical trial evaluating palifermin combined with alemtuzumab in multiple sclerosis patients. The trial was sponsored by Cambridge University Hospitals NHS Foundation Trust and registered in 2012. The study was terminated before completion, and no results data are publicly reported in the available abstract.
Study Limitations
The trial was terminated before completion, meaning no efficacy or safety conclusions can be drawn. This summary is based on the abstract and trial registration only — no results data, participant numbers, or reasons for termination are available. The 2012 registration date suggests this is older, potentially superseded research.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: